Using healthcare systems data for outcomes in clinical trials: issues to consider at the design stage

Toader, Alice-Maria, Campbell, Marion K., Quint, Jennifer K., Robling, Michael ORCID: https://orcid.org/0000-0002-1004-036X, Sydes, Matthew R, Thorn, Joanna, Wright-Hughes, Alexandra, Yu, Ly-Mee, Abbott, Tom. E. F., Bond, Simon, Caskey, Fergus J., Clout, Madeleine, Collinson, Michelle, Copsey, Bethan, Davies, Gwyneth, Driscoll, Timothy, Gamble, Carrol, Griffin, Xavier L., Hamborg, Thomas, Harris, Jessica, Harrison, David A., Harji, Deena, Henderson, Emily J., Logan, Pip, Love, Sharon B., Magee, Laura A., O’Brien, Alastair, Pufulete, Maria, Ramnarayan, Padmanabhan, Saratzis, Athanasios, Smith, Jo, Solis-Trapala, Ivonne, Stubbs, Clive, Farrin, Amanda and Williamson, Paula 2024. Using healthcare systems data for outcomes in clinical trials: issues to consider at the design stage. Trials 25 , 94. 10.1186/s13063-024-07926-z

	PDF - Supplemental Material Available under License Creative Commons Attribution. Download (92kB)
	PDF - Published Version Available under License Creative Commons Attribution. Download (1MB)

Abstract

Background: Healthcare system data (HSD) are increasingly used in clinical trials, augmenting or replacing traditional methods of collecting outcome data. This study, PRIMORANT, set out to identify, in the UK context, issues to be considered before the decision to use HSD for outcome data in a clinical trial is finalised, a methodological question prioritised by the clinical trials community. Methods: The PRIMORANT study had three phases. First, an initial workshop was held to scope the issues faced by trialists when considering whether to use HSDs for trial outcomes. Second, a consultation exercise was undertaken with clinical trials unit (CTU) staff, trialists, methodologists, clinicians, funding panels and data providers. Third, a final discussion workshop was held, at which the results of the consultation were fed back, case studies presented, and issues considered in small breakout groups. Results: Key topics included in the consultation process were the validity of outcome data, timeliness of data capture, internal pilots, data-sharing, practical issues, and decision-making. A majority of consultation respondents (n = 78, 95%) considered the development of guidance for trialists to be feasible. Guidance was developed following the discussion workshop, for the five broad areas of terminology, feasibility, internal pilots, onward data sharing, and data archiving. Conclusions: We provide guidance to inform decisions about whether or not to use HSDs for outcomes, and if so, to assist trialists in working with registries and other HSD providers to improve the design and delivery of trials.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Additional Information:	License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by/4.0/, Type: open-access
Publisher:	BioMed Central
ISSN:	1745-6215
Date of First Compliant Deposit:	30 January 2024
Date of Acceptance:	12 January 2024
Last Modified:	23 Feb 2024 15:30
URI:	https://orca.cardiff.ac.uk/id/eprint/165915

Actions (repository staff only)

Edit Item